

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM326564

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Trademark Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
PDL BioPharma, Inc.		12/16/2014	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Durata Therapeutics Holding C.V.		
Street Address:	190 Elgin Avenue		
City:	George Town, Grand Cayman		
State/Country:	CAYMAN ISLANDS		
Postal Code:	KY1-9005		
Entity Type:	LIMITED PARTNERSHIP: NETHERLANDS		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Serial Number:	85741315	DALVANCE	
Registration Number:	4345429	DURATA THERAPEUTICS	
Registration Number:	4300433	DURATA THERAPEUTICS	
Serial Number:	85741328	XYDALBA	
CORRESPONDENCE DATA			
Fax Number:	6175265000		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	617-526-6448		
Email:	huelinh.tran@wilmerhale.com		
Correspondent Name:	Michael J. Bevilacqua, Esq.		
Address Line 1:	Wilmer Cutler Pickering Hale and DorrLLP		
Address Line 2:	60 State Street		
Address Line 4:	Boston, MASSACHUSETTS 02109		
ATTORNEY DOCKET NUMBER:	2205.364.129		
DOMESTIC REPRESENTATIVE			
Name:	Michael J. Bevilacqua, Esq.		
Address Line 1:	Wilmer Cutler Pickering Hale and DorrLLP		
Address Line 2:	60 State Street		
Address Line 4:	Boston, MASSACHUSETTS 02109		

OP \$115.00 85741315

NAME OF SUBMITTER:	Michael J. Bevilacqua
SIGNATURE:	/michael j. bevilacqua/
DATE SIGNED:	12/18/2014
Total Attachments: 2 source=release trademark security agreement pdl biopharma to durata therapeutics holding#page1.tif source=release trademark security agreement pdl biopharma to durata therapeutics holding#page2.tif	

RELEASE OF TRADEMARK SECURITY AGREEMENT

WHEREAS, Durata Therapeutics Holding C.V., a limited partnership organized under the laws of the Netherlands (the "Grantor"), entered into that certain Trademark Security Agreement (the "Agreement"), dated as of October 31, 2013, which was recorded in the United States Patent and Trademark Office on October 31, 2013 at Reel 5143 and Frame 0272, that by its terms granted to PDL BioPharma, Inc., a Delaware corporation (the "Lender"), a security interest and continuing lien in the Trademark Collateral (as defined in the Agreement) in favor of the Lender; and

WHEREAS, the Lender has agreed to terminate and release the entirety of its security interest in the Trademark Collateral;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, effective as of even date herewith, the Lender hereby irrevocably (a) releases, relinquishes, terminates and discharges its security interest in the Trademark Collateral, including the registrations and applications listed on Exhibit A hereto, and (b) reassigns any and all such right, title and interest (if any) that the Lender may have in the Trademark Collateral to the Grantor, and any right, title or interest of the Lender in such Trademark Collateral shall hereby immediately cease and become void. The Lender further agrees, for itself, its successors and assigns, to execute such further documents and to perform such further lawful acts as may reasonably be requested by the Grantor, to effectuate this release.

The Lender acknowledges that it is the purpose of this document to memorialize the aforementioned release of its security interest in the Trademark Collateral in a form suitable for recordation in the United States Patent and Trademark Office and hereby consents to the recording of this document in the United States Patent and Trademark Office.

IN WITNESS WHEREOF the Lender by the signature below of its duly authorized representative agrees to be bound by the provisions of this release agreement as of the date of execution, this 10 day of December, 2014.

PDL BIOPHARMA, INC.


Name: Christopher Stone
Title: VP and General Counsel

Exhibit A

TRADEMARK SECURITY INTEREST RELEASE

<u>Trademark</u>	<u>Application/Registration Number</u>	<u>Filing/Registration Date</u>
DALVANCE	85/741,315	09/28/2012
DURATA THERAPEUTICS	4,345,429	06/04/2013
DURATA THERAPEUTICS and design	4,300,433	03/12/2013
XYDALBA	85/741,328	09/28/2012